About CLTI
Technology
- Products
Clinical Evidence
U.S. Clinical Trial
Company
Contact
International

June 6 2017

LimFlow Expands Senior Management Team and Opens Silicon Valley Office

View the article.

LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients Midterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia

Related Posts

LimFlow System Demonstrates Excellent Sustained Amputation-Free Survival and Wound Healing at One Year in PROMISE I U.S. Study

Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia

First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-Threatening Ischemia

Recent Posts

LimFlow System Demonstrates Excellent Sustained Amputation-Free Survival and Wound Healing at One Year in PROMISE I U.S. Study
Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia
First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-Threatening Ischemia
LimFlow Announces Positive Six-month Data From PROMISE I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-option Patient Population
Limflow Receives FDA Approval for U.S. Pivotal Study of Minimally-Invasive Technology Designed to Prevent Amputations in Chronic Limb-Threatening Ischemia Patients

LimFlow, Inc.
2934 Scott Boulevard
Santa Clara, CA 95054 USA

info@limflow.com
+1 (888) 478-7705
+1 (408) 898-1459

CAUTION: Investigational device. Limited by Federal law to investigational use.

©2020 LimFlow SA | Site designed by The Deciding Factor, Inc.